HIKAL vs WOCKPHARMA: Stock Comparison

HIKAL vs WOCKHARDTUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

WOCKHARDT is the larger company by market capitalisation. HIKAL shows a lower P/E, a higher dividend yield and faster revenue growth, while WOCKHARDT shows a higher ROE, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

HIKAL leads 7; WOCKPHARMA leads 5 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

HIKALWOCKPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹2,740 Cr
₹33,908 Cr
P/E RatioHIKAL has the lower reading
0x
75.68x
P/B RatioHIKAL has the lower reading
2.07x
6.27x
EPSWOCKPHARMA has the higher reading
₹-0.6
₹6.58
Book ValueContext only
₹97.23
₹325
Dividend YieldHIKAL has the higher reading
0.09%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹33,908 Cr vs ₹2,740 Cr
P/E Ratio
HIKAL has a lower P/E
0x vs 75.68x
P/B Ratio
HIKAL has a lower P/B
2.07x vs 6.27x
EPS
WOCKPHARMA has higher earnings per share
₹6.58 vs ₹-0.6
Dividend Yield
HIKAL has a higher dividend yield
0.09% vs 0%
Revenue Growth (TTM YoY)
HIKAL has faster revenue growth
37.3% vs 26%
EPS Growth (TTM YoY)
HIKAL has faster EPS growth
68.3% vs 0%
Qtr Sales Growth
HIKAL has stronger quarterly sales growth
0% vs -39.61%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricHIKALWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricHIKALWOCKPHARMA
Live Price₹222.3₹2,088.7
Day Change-7.51%7.08%
Volume53.59 L35.58 L
52-Week High₹282.7₹2,422.3
52-Week Low₹146.25₹1,086.7
Distance from 52W High-21.37%-13.77%

Valuation

MetricHIKALWOCKPHARMA
Market Cap₹2,740 Cr₹33,908 Cr
P/E Ratio0x75.68x
P/B Ratio2.07x6.27x
EPS₹-0.6₹6.58
Book Value₹97.23₹325
Dividend Yield0.09%0%

Growth

MetricHIKALWOCKPHARMA
Revenue Growth (TTM YoY)37.3%26%
EPS Growth (TTM YoY)68.3%0%
Qtr Sales Growth0%-39.61%
Qtr Profit Growth1.33%0%

Profitability & Leverage

MetricHIKALWOCKPHARMA
ROE-4.07%10.28%
ROCE-0.87%10.37%
Net Margin-2.88%3.3%
Operating Margin-0.95%28.35%
Debt to Equity0.57x0.57x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricHIKALWOCKPHARMA
Promoter Holding68.85%49.08%
FII Holding0.99% 0.44 pp7.22% 0.13 pp
DII Holding7.24% 0.04 pp9.24% 1.72 pp
Public Holding22.93% 0.41 pp34.44% 1.61 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: HIKAL and WOCKHARDT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.